Eli Lilly's Once-Weekly Insulin Shows Positive A1C Reductions in Phase 3 Trials

Sep 5, 2024, 10:57 AM

Eli Lilly announced positive topline data from its QWINT-1 and QWINT-3 Phase 3 clinical trials evaluating once-weekly insulin efsitora alfa in adults with type 2 diabetes. The trials demonstrated that the insulin led to non-inferior A1C reductions similar to daily insulin regimens, meeting their primary endpoints. This fixed dose study is the first of its kind, showcasing the potential of once-weekly insulin treatments for diabetes management.